Evotec, Bristol Myers Squibb Expand Proteomics Pact

Evotec SE has expanded its strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a program-based payment of $50 million to Evotec. 
 
The companies entered their strategic protein degradation partnership in 2018 and expanded it in May of 2022, based on the highly productive initial collaboration generating a promising pipeline. Since the expansion, Evotec has significantly scaled up its activities to develop highly promising compounds from Bristol Myers Squibb’s library of cereblon E3 ligase modulators (CELMoDs). The partnership continues to deliver, adding a broad pipeline of novel molecular glue degraders for high-value targets, in this case for fields beyond oncology.
 
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “We are delighted to expand our successful partnership with Bristol Myers Squibb into fields beyond oncology with a significant unmet medical need. The unique mode of action, combined with drug-likeness and oral administration make molecular glue degraders a promising and versatile therapeutic option. Our partnership with BMS continues to build an extraordinary pipeline of first-in-class product opportunities and we look forward to driving the joint portfolio of programs towards clinical validation for the benefit of patients.”